Immunotherapy for Bladder Cancer

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2002 Jun 27

PMID 12084297

Citations 15

Authors

A M Kamat

D L Lamm

Affiliations

Soon will be listed here.

Abstract

The primary role of immunotherapy for bladder cancer is to treat superficial transitional cell carcinomas (ie, carcinoma in situ, Ta, and T1). Immunotherapy in the form of bacille Calmette-Guérin (BCG), interferon, bropirimine, keyhole limpet hemocyanin, and gene therapy is intended to treat existing or residual tumor, to prevent recurrence of tumor, to prevent progression of disease, and to prolong survival of patients. Presently, BCG is commonly used and is the most effective immunotherapeutic agent against superficial transitional cell carcinoma. Data support that BCG has a positive impact on tumor recurrence, disease progression, and survival. Proper attention to maintenance schedules, route of administration, dosing, strains, and viability is essential to obtain the maximum benefits of BCG immunotherapy. This review highlights and summarizes the recent advances concerning immunotherapy, with special emphasis on BCG therapy for transitional cell carcinoma.

Citing Articles

Ahmadi S, Ambite I, Brisuda A, Hacek J, Haq F, Sabari S Cancer Med. 2024; 13(7):e7091.

PMID: 38553868 PMC: 10980842. DOI: 10.1002/cam4.7091.

BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets.

Claps F, Pavan N, Ongaro L, Tierno D, Grassi G, Trombetta C Int J Mol Sci. 2023; 24(16).

PMID: 37628785 PMC: 10454200. DOI: 10.3390/ijms241612596.

From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC).

Deininger S, Torzsok P, Mitterberger M, Pallauf M, Oswald D, Deininger C Cancers (Basel). 2022; 14(3).

PMID: 35158964 PMC: 8833656. DOI: 10.3390/cancers14030694.

Dual Nature of Relationship between Mycobacteria and Cancer.

Fol M, Kozinski P, Kulesza J, Bialecki P, Druszczynska M Int J Mol Sci. 2021; 22(15).

PMID: 34361097 PMC: 8347776. DOI: 10.3390/ijms22158332.

Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated .

Hernandez-Luna M, Luria-Perez R J Immunol Res. 2018; 2018:2984247.

PMID: 30302344 PMC: 6158935. DOI: 10.1155/2018/2984247.

References

Lamm D, Dehaven J, Shriver J, Sarosdy M . Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer. J Urol. 1991; 145(4):738-40. DOI: 10.1016/s0022-5347(17)38439-2. View

Jurincic C, Engelmann U, Gasch J, Klippel K . Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol. 1988; 139(4):723-6. DOI: 10.1016/s0022-5347(17)42610-3. View

Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K . Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer. 1995; 75(2):552-9. DOI: 10.1002/1097-0142(19950115)75:2<552::aid-cncr2820750219>3.0.co;2-h. View

Torti F, Shortliffe L, Williams R, Pitts W, Kempson R, Ross J . Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol. 1988; 6(3):476-83. DOI: 10.1200/JCO.1988.6.3.476. View

Becich M, Carroll S, Ratliff T . Internalization of bacille Calmette-Guerin by bladder tumor cells. J Urol. 1991; 145(6):1316-24. DOI: 10.1016/s0022-5347(17)38622-6. View

Coplen D, Marcus M, Myers J, Ratliff T, Catalona W . Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol. 1990; 144(3):652-7. DOI: 10.1016/s0022-5347(17)39546-0. View

Lamm D . Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am. 1992; 19(3):573-80. View

Klein E, Rogatko A, Herr H . Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J Urol. 1992; 147(3):601-5. DOI: 10.1016/s0022-5347(17)37317-2. View

Riggs D, Dehaven J, Lamm D . Allium sativum (garlic) treatment for murine transitional cell carcinoma. Cancer. 1997; 79(10):1987-94. DOI: 10.1002/(sici)1097-0142(19970515)79:10<1987::aid-cncr21>3.0.co;2-q. View

10.

Witjes W, Konig M, Boeminghaus F, Hall R, Schulman C, Zurlo M . Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur Urol. 1999; 36(6):576-81. DOI: 10.1159/000020051. View

11.

BROSMAN S . Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1982; 128(1):27-30. DOI: 10.1016/s0022-5347(17)52736-6. View

12.

Hudson M, Yuan J, Catalona W, Ratliff T . Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol. 1990; 144(6):1362-4. DOI: 10.1016/s0022-5347(17)39741-0. View

13.

Mungan N, Witjes J . Bacille Calmette-Guérin in superficial transitional cell carcinoma. Br J Urol. 1998; 82(2):213-23. DOI: 10.1046/j.1464-410x.1998.00720.x. View

14.

Boccardo F, Cannata D, Rubagotti A, Guarneri D, DeCensi A, Canobbio L . Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J Clin Oncol. 1994; 12(1):7-13. DOI: 10.1200/JCO.1994.12.1.7. View

15.

DAncona C, Netto Junior N, Claro J, Ikari O . Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma. J Urol. 1991; 145(3):498-501. DOI: 10.1016/s0022-5347(17)38379-9. View

16.

Corti Ortiz D, Rivera Garay P, Aviles Jasse J, Hidalgo Carmona F, MacMillan Soto G, Coz Canas L . [Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG: comparison with other doses]. Actas Urol Esp. 1993; 17(4):239-42. View

17.

Orsola A, Palou J, Xavier B, Algaba F, Salvador J, Vicente J . Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur Urol. 1998; 33(5):457-63. DOI: 10.1159/000019635. View

18.

Lamm D . Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol. 1985; 134(1):40-7. DOI: 10.1016/s0022-5347(17)46972-2. View

19.

Abel P . Follow-up of patients with "superficial" transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol. 1993; 72(2):135-42. DOI: 10.1111/j.1464-410x.1993.tb00674.x. View

20.

Herr H, Laudone V, Badalament R, Oettgen H, Sogani P, Freedman B . Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol. 1988; 6(9):1450-5. DOI: 10.1200/JCO.1988.6.9.1450. View